Posted by Michael Wonder on 02 Jan 2025
NRx Pharmaceuticals files initial section of US new drug application to the FDA for NRX-100 (IV ketamine) for the treatment of suicidal depression
30 December 2024 - Aiming to be the first FDA approved medication to treat suicidal depression.
NRx Pharmaceuticals today announced the transmission of first section of its new drug application for NRX-100 (ketamine) for electronic filing with the US FDA.
